Valion Bio (VBIO) Operating Expenses (2021 - 2025)

Valion Bio has reported Operating Expenses for 5 years, with the latest figure at $2.3 million in Q3 2025.

• On a quarterly basis, Operating Expenses rose 58.51% year-over-year to $2.3 million in Q3 2025; TTM through Sep 2025 was $7.1 million, a 6.87% increase from a year earlier, with the FY2024 full-year figure at $5.7 million, down 33.63% from the prior year.
• Operating Expenses was $2.3 million for Q3 2025 at Valion Bio, up from $2.0 million in the prior quarter.
• The five-year high for Operating Expenses was $3.1 million in Q2 2022, with the low at $1.0 million in Q2 2021.
• Average Operating Expenses over 5 years is $1.9 million, with a median of $2.0 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses soared 207.53% in 2022, then plunged 44.69% in 2024.
• Over 5 years, Operating Expenses stood at $2.3 million in 2021, then climbed by 0.39% to $2.3 million in 2022, then retreated by 2.17% to $2.2 million in 2023, then slumped by 44.69% to $1.2 million in 2024, then soared by 87.94% to $2.3 million in 2025.
• The last three Operating Expenses figures came in at $2.3 million (Q3 2025), $2.0 million (Q2 2025), and $1.6 million (Q1 2025), per Business Quant data.